drugset / Trial / NCT02696954

Study of Artemether-lumefantrine, Amodiaquine and Primaquine in Healthy Subjects

NCT02696954

RandomizedParallel-groupOpen-labelTreatment

Summary

Primary Objective * To characterize the potential pharmacokinetic interactions of artemether -lumefantrine, amodiaquine and primaquine in healthy adult subjects. Secondary Objectives * To characterize the pharmacokinetic properties of artemether-lumefantrine, amodiaquine and primaquine when given alone and in combination. * To evaluate the safety and tolerability of co-administered artemether-lumefantrine, amodiaquine and primaquine. * To investigate pharmacogenetic polymorphisms affecting drug levels of artemether-lumefantrine, amodiaquine and primaquine and their metabolites.

Timeline

Start
2016-11-18
Primary completion
2019-03
Completion
2019-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Artemether-lumefantrine Unknown
Subject Primaquine Small molecule
Subject amodiaquine Other / unclassified

Indications

No indication recorded.